January 7, 2026 did not arrive with fireworks, but it landed with weight. IMVARIA out of Berkeley just secured strategic investment led by InHealth Ventures, joined by Labcorp Venture Fund and...
January 7, 2026 did not arrive with fireworks, but it landed with weight. IMVARIA out of Berkeley just secured strategic investment led by InHealth Ventures, joined by Labcorp Venture Fund and returning partner Cedar Crest Holdings. No headline number, no victory lap. Just capital that knows when to speak softly and move precisely, especially in medicine where volume rarely equals value.
IMVARIA lives in the uncomfortable middle where lung disease hides. Late diagnoses. Invasive biopsies. Too many maybes and not enough time. Founded in 2019 by Dr. Joshua Reicher and Dr. Michael Muelly, both Stanford-trained physicians with Google reps and real clinical mileage, the company looked at chest CTs and asked a smarter question. What if the data already knew more than we were listening for.
Fibresolve answered first. FDA De Novo authorized January 2024. Breakthrough designated. Paired with AMA-adopted CPT billing codes. A rare regulatory triple crown. Not theoretical AI. Not demo-day optimism. A real software as medical device diagnosing IPF and ILD without cutting patients open. Non-invasive. Cloud-based. Ordered like a lab test. Results back in minutes. Medicine that respects time, cost, and anatomy.
ScreenDx followed in January 2025 with FDA 510(k) clearance, quietly scanning thousands of CTs in the background to surface ILD before it disappears into delay. No workflow disruption. No extra clicks. Just signal where noise used to live. Then Bronchosolve showed up in October 2025, meeting primary endpoints in the VIRTUAL-BRONCH Study for noninvasive lung cancer diagnosis, across screening and non-screening cases. Same philosophy. Higher stakes.
This is why InHealth Ventures leaned in, bringing global diagnostic scale from the UK. Why Labcorp Venture Fund stepped up, recognizing a platform that fits how care actually moves. And why Cedar Crest Holdings stayed close. Momentum respects preparation.
Dr. Joshua Reicher has lived inside medical AI long enough to understand that credibility compounds slowly and disappears instantly. Dr. Michael Muelly builds like someone who still reads scans and still feels friction at the bedside. Together they engineered a centralized AI service model clinicians trust because it does not ask them to become something else.
ILD affects approximately 650k people in the US. IPF survival clocks do not forgive delays. Lung nodules appear in 1.5M Americans every year. IMVARIA is not promising certainty. It is delivering earlier clarity, backed by FDA authorizations, reimbursement pathways, NIH SBIR support, Mayo Clinic collaboration, Viz.ai integration, and expanding access across MENA through Medical Horizons.